TG Therapeutics, Inc. (TGTX - Free Report) was a big mover last session, as the company saw its shares rise over 9% on the day. The company announced that the U.S. Food and Drug Administration has granted orphan drug designation for its oral, next generation PI3K Delta inhibitor, TGR-1202. The news led to far more shares changing hands than in a normal session resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.49 to $6.39 in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revisions of one increase and four decreases over the past one month, while the Zacks Consensus Estimate moved lower over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this stock in the near future.
TG Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
TG THERAPEUTICS Price
A better-ranked stock in the same industry is GW Pharmaceuticals plc , sporting a Zacks Rank #1 (Strong Buy).
Is TGTX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
TG Therapeutics, Inc. (TGTX - Free Report) was a big mover last session, as the company saw its shares rise over 9% on the day. The company announced that the U.S. Food and Drug Administration has granted orphan drug designation for its oral, next generation PI3K Delta inhibitor, TGR-1202. The news led to far more shares changing hands than in a normal session resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.49 to $6.39 in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revisions of one increase and four decreases over the past one month, while the Zacks Consensus Estimate moved lower over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this stock in the near future.
TG Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
TG THERAPEUTICS Price
A better-ranked stock in the same industry is GW Pharmaceuticals plc , sporting a Zacks Rank #1 (Strong Buy).
Is TGTX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TGTX - FREE